^
    Back
    Association details:
    Biomarker:ALK F1174L
    Cancer:Neuroblastoma
    Drug:Alecensa (alectinib) (ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Cancer Cell
    Title:

    CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant

    Excerpt:
    ...inhibitory potency of CH5424802 to F1174L in both a cell-free kinase assay and an antiproliferative assay using the neuroblastoma KELLY cell line that expresses F1174L (Table S2)...The inhibitory activity in vitro to F1174L (IC50 = 1.0 nM)…
    DOI:
    10.1016/j.ccr.2011.04.004